Cargando…

SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma

Background: Cabergoline is first-line treatment for prolactin-secreting pituitary macroadenoma (prolactinoma). Side effects such as nausea, valvulopathy and neuropsychiatric symptoms are well recognized complications of its use. A rare complication is vision loss secondary to empty-sella syndrome. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Balzac, Carlos A, Williams, Zoe R, Vates, G Edward, Shafiq, Ismat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207920/
http://dx.doi.org/10.1210/jendso/bvaa046.1151
_version_ 1783530718986502144
author Díaz-Balzac, Carlos A
Williams, Zoe R
Vates, G Edward
Shafiq, Ismat
author_facet Díaz-Balzac, Carlos A
Williams, Zoe R
Vates, G Edward
Shafiq, Ismat
author_sort Díaz-Balzac, Carlos A
collection PubMed
description Background: Cabergoline is first-line treatment for prolactin-secreting pituitary macroadenoma (prolactinoma). Side effects such as nausea, valvulopathy and neuropsychiatric symptoms are well recognized complications of its use. A rare complication is vision loss secondary to empty-sella syndrome. Clinical case: A 27-years old women was diagnosed in 2009 with macroprolactinoma with a prolactin level of 2,523.91ng/mL (normal 3.3-26.7ng/mL), during work up of frontal headaches, amenorrhea and infertility. The rest of her pituitary work up was normal. She was started on dopamine receptor agonist therapy with Cabergoline 0.25mg two times a week. Her headaches improved within a few month. The prolactin level normalized and MRI at 1 year after starting Cabergoline therapy showed significant decrease in pituitary adenoma to 3mm. She continued Cabergoline therapy for 3 years, after which time it was discontinued. For the next 6-8 years she was on and off Cabergoline therapy for mild elevation of prolactin and galactorrhea/headache symptoms, with improvement of symptoms on Cabergoline. However, nine years after diagnosis and Cabergoline treatment, she developed vision loss, characterized by bitemporal hemianopia. MRI showed partial empty sella with downward displacement of the optic chiasm. Cabergoline therapy was stopped with some improvement of visual symptoms on exam. Here latest prolactin level is at 134ng/ml. Surgical management with chiasmapexy is being explored. Conclusion: Vision loss secondary to optic nerve traction from chiasmal herniation in the setting of an empty sella can be a consequence of Cabergoline therapy. No predictors or risk factors are known for the development of this complication. Furthermore, no clear evidence is available of benefit from discontinuation/continuation of therapy. Novel surgical management with chiasmapexy is being explored as a solution to stabilize the optic chiasm and resolve visual symptoms without further complications.
format Online
Article
Text
id pubmed-7207920
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72079202020-05-13 SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma Díaz-Balzac, Carlos A Williams, Zoe R Vates, G Edward Shafiq, Ismat J Endocr Soc Neuroendocrinology and Pituitary Background: Cabergoline is first-line treatment for prolactin-secreting pituitary macroadenoma (prolactinoma). Side effects such as nausea, valvulopathy and neuropsychiatric symptoms are well recognized complications of its use. A rare complication is vision loss secondary to empty-sella syndrome. Clinical case: A 27-years old women was diagnosed in 2009 with macroprolactinoma with a prolactin level of 2,523.91ng/mL (normal 3.3-26.7ng/mL), during work up of frontal headaches, amenorrhea and infertility. The rest of her pituitary work up was normal. She was started on dopamine receptor agonist therapy with Cabergoline 0.25mg two times a week. Her headaches improved within a few month. The prolactin level normalized and MRI at 1 year after starting Cabergoline therapy showed significant decrease in pituitary adenoma to 3mm. She continued Cabergoline therapy for 3 years, after which time it was discontinued. For the next 6-8 years she was on and off Cabergoline therapy for mild elevation of prolactin and galactorrhea/headache symptoms, with improvement of symptoms on Cabergoline. However, nine years after diagnosis and Cabergoline treatment, she developed vision loss, characterized by bitemporal hemianopia. MRI showed partial empty sella with downward displacement of the optic chiasm. Cabergoline therapy was stopped with some improvement of visual symptoms on exam. Here latest prolactin level is at 134ng/ml. Surgical management with chiasmapexy is being explored. Conclusion: Vision loss secondary to optic nerve traction from chiasmal herniation in the setting of an empty sella can be a consequence of Cabergoline therapy. No predictors or risk factors are known for the development of this complication. Furthermore, no clear evidence is available of benefit from discontinuation/continuation of therapy. Novel surgical management with chiasmapexy is being explored as a solution to stabilize the optic chiasm and resolve visual symptoms without further complications. Oxford University Press 2020-05-08 /pmc/articles/PMC7207920/ http://dx.doi.org/10.1210/jendso/bvaa046.1151 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Díaz-Balzac, Carlos A
Williams, Zoe R
Vates, G Edward
Shafiq, Ismat
SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
title SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
title_full SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
title_fullStr SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
title_full_unstemmed SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
title_short SAT-275 Bitemporal Hemianopia as a Result of Cabergoline Therapy for Macroprolactinoma
title_sort sat-275 bitemporal hemianopia as a result of cabergoline therapy for macroprolactinoma
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207920/
http://dx.doi.org/10.1210/jendso/bvaa046.1151
work_keys_str_mv AT diazbalzaccarlosa sat275bitemporalhemianopiaasaresultofcabergolinetherapyformacroprolactinoma
AT williamszoer sat275bitemporalhemianopiaasaresultofcabergolinetherapyformacroprolactinoma
AT vatesgedward sat275bitemporalhemianopiaasaresultofcabergolinetherapyformacroprolactinoma
AT shafiqismat sat275bitemporalhemianopiaasaresultofcabergolinetherapyformacroprolactinoma